KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 4

Predictive Biomarkers in Late Onset Neutropenia Associated with Rituximab

Mahmut BUYUKŞİMŞEK
Semra PAYDAŞ
Ali OĞUL
Abdullah Evren YETİŞİR
Cem MİRİLİ
Sayfa
428–432
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Mean rituximab dose was 4870 mg incases developing neutropenia while it was 4162 mg in cases without neutropenia.Conclusion: Lower NLR at the end of treatment cycle, G-CSF using with prophylaxis aim, extranodal involvement andmore than 4 gr rituximab using were found as the predictive factors for LON associated with rituximab.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of this study is to determine the biomarkers in LON (Late Onset Neutropenia) associated withrituximab using in lymphoproliferative diseases (LPDs).Methods: : In this retrospective study 22 cases with LPD treated by rituximab containing regimen and followed at leastone year in our center were evaluated for LON.Results: Grade I, II and IV neutropenia were detected in five, five and one cases, respectively.
📊
Temel Bulgular & Veri:Lowest neutrophil/lymphocyte ratio (NLR) was 1.2 and 1.7 in cases with and without LON, respectively.
💡
Sonuç & Katkı:Mean rituximab dose was 4870 mg incases developing neutropenia while it was 4162 mg in cases without neutropenia.Conclusion: Lower NLR at the end of treatment cycle, G-CSF using with prophylaxis aim, extranodal involvement andmore than 4 gr rituximab using were found as the predictive factors for LON associated with rituximab.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: The aim of this study is to determine the biomarkers in LON (Late Onset Neutropenia) associated withrituximab using in lymphoproliferative diseases (LPDs).Methods: : In this retrospective study 22 cases with LPD treated by rituximab containing regimen and followed at leastone year in our center were evaluated for LON.Results: Grade I, II and IV neutropenia were detected in five, five and one cases, respectively. Lowest neutrophil/lymphocyte ratio (NLR) was 1.2 and 1.7 in cases with and without LON, respectively. Neutropenia developed in 8 of 15 caseswith Diffuse large B cell lymphoma (DLBCL), 2 of 2 cases with Follicular Lymphoma (FL) and one case of Small lymphocytic lymphoma (SLL). According to prophylactic Granulocyte colony-stimulating factor (G-CSF) using, neutropenia wasdetected in all cases given prophylaxis while 6 of 17 cases without prophylaxis. Mean rituximab dose was 4870 mg incases developing neutropenia while it was 4162 mg in cases without neutropenia.Conclusion: Lower NLR at the end of treatment cycle, G-CSF using with prophylaxis aim, extranodal involvement andmore than 4 gr rituximab using were found as the predictive factors for LON associated with rituximab.

🔖

Bu Makaleye Atıf Yap

BUYUKŞİMŞEK, M., PAYDAŞ, S., OĞUL, A., YETİŞİR, A. E., MİRİLİ, C. (2022). Predictive Biomarkers in Late Onset Neutropenia Associated with Rituximab. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 4, 428–432. https://ajindex.com/articles/508662

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Randall KL. Rituximab in autoimmune diseases. Australian prescriber 2016;39:131–34
  2. Moore DC. Drug-Induced Neutropenia: A Focus on RituximabInduced Late-Onset Neutropenia. P T 2016;41:765–8
  3. Grillo-López AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000;27:9–16
  4. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389–97
  5. Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 2011;4:619–25
  6. Saikia TK, Menon H, Advani SH. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. Ann Oncol 2001;12:1493–4
  7. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–20
  8. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308–18
  9. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 1997;89:256–60
  10. Liu JH, Wei S, Lamy T, Epling-Burnette PK, Starkebaum G, Djeu JY, et al. Chronic neutropenia mediated by fas ligand. Blood 2000;95:3219–22
  11. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximabtreated lymphoma patients: report of two cases. Leuk Res 2002;26:597–600
  12. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayedonset neutropenia associated with rituximab therapy. Br J Haematol 2003;121:913–8
  13. Voog E, Morschhauser F, Solal-Céligny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691–4
  14. Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008;25:374–9
  15. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed-onset peripheral blood cyto